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It is well recognised that the adenoma-carcinoma sequence is the mechanism by 
which most colorectal malignancies arise.  Dysplastic adenomas are the precursor 
lesions which can progress to adenocarcinoma and premalignant sessile villous 
adenomas represent a particular challenge.  Their early detection and removal can 
prevent rectal cancer.  Local excision of low rectal tumors has become increasingly 
popular as technical advancement has rendered it easier and more effective.  Local 
tumour excision avoids the complications of radical surgery.  Transanal endoscopic 
operation (TEO) and Transanal endoscopic microsurgery (TEM) are two equivalent 
techniques that have been widely adopted as the treatments of choice for large rectal 
adenomas and selected rectal cancers but has been under-employed in South 
Africa.   
 
The aim of this study was to evaluate TEO (the simpler and more affordable platform 
of the two) by describing the dimensions and anatomical parameters of specimens 
resected and using this to investigate whether any of these are predictive of 




In this single surgeon study, data was collected from pre-existing patient files (paper 
and electronic) during the first half of the time period and during the second half, was 
prospectively entered into a database.  It includes all patients undergoing resection 
of benign and malignant rectal tumours by TEO at a private (Kingsbury Hospital) and 
public health institution (Groote Schuur Hospital) from January 2009 – May 2017.  
Electronic records, including operation notes, histology and radiology were reviewed. 
 
Results 
Data was collected from January 2009 to May 2017.  110 patients in this study of 
which 87 (79.1%) were benign.  There were 11 (12%) recurrences in this group.  In 
the malignant group, there were 5 (21%) recurrences.  The median tumour length 
was 4.5cm (IQR 2.5) and median tumour area was 16cm2 (IQR 20.11).   
 
For benign lesions, there was a significant difference in recurrence in patients 
presenting with incontinence (χ2 8.21, p-value<0.01, OR 16.7 (1.37-202.7)), lesions 
with involved surgical margins (χ2 6.29 p-value 0.01, OR 6.75 (95% CI 1.02 - 35.7)) 
and circumferential tumours (χ2 6.31 p-value 0.04, 6.5 (1.17-36.3)).  The multinomial 
logistic regression model for benign lesions revealed that only incontinence and 
involved surgical margins were independent predictors of recurrence.  Complications 
occurred in 21 (19.1%) patients with circumferential lesions, length of the tumour, 
and malignancy being predictive of complications. 
 
Conclusion 
This study constitutes the only report of TEO or TEM from a low- or middle-income 
country (LMIC).  The results are in keeping with the published literature, 
demonstrating its safety and feasibility in a LMIC setting, which will reduce the need 
for expensive, highly morbid radical surgery for benign and malignant disease.  The 
recommendation is for a wider introduction of TEO in South Africa and other LMIC 





































































Colorectal cancer is one of the leading causes of death in developed countries, 
with a mortality rate of 8% (608 per 100 000).  In men, it is the 4th most common 
cause of death (mortality rate 7.6%; 320 deaths per 100 000), after lung cancer 
(mortality rate 22.5%, 951 deaths per 100 000), stomach cancer (mortality rate 
11%, 464 deaths per 100 000) and prostate cancer (mortality rate 6.1%, 258 
deaths per 100 000).  In women, it is the 3rd most common cause of death 
(mortality rate of 8.6%; 288 deaths per 100 000), after breast cancer (mortality 
rate of 13.7%; 458 deaths per 100 000) and lung cancer (mortality rate of 12.8%; 
427 deaths per 100 000).1 
 
Worldwide, incidence rates vary in both sexes. It was found to be the third most 
common cancer in men with an incidence of 10% (663 new cases per 100 000), 
after lung cancer (incidence rate of 16.5%; 1095 per 100 000) and prostate 
cancer (incidence rate of 13.8%; 913 per 100 000 person years) and third most 
common cancer worldwide.  It is the second most common cancer in women 
(incidence rate of 9.4%; 570 new cases per 100 000) after breast cancer.1,2 
 
Overall, the rates in Australia/New Zealand and Western Europe were estimated 
to be the highest compared to those in South Central Asia and Africa (except 
Southern Africa) being the lowest.1 A study, comparing the incidence rates of 
colorectal cancer from 1982-87 to 1998-2002, found that the rates increased for 
both males and females in 27 of the 51 registries reviewed.  This increase 
appeared to be limited to developing or ‘economically transitioning’ countries 
(Czech Republic, Slovakia and Japan) and exceeded the incidence in well-
established developed countries (United States, Canada and Australia).  The 
factors which may have contributed to this variation in incidence are synonymous 
with those associated with economic development and include the difference in 
prevalence of risk factors for colorectal cancer (obesity, physical inactivity, 
smoking, heavy alcohol consumption, a diet high in red or processed meats, a 
diet low in fruits and vegetables) and the difference in screening practices.3,4 
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Most recent statistics reported by the American Cancer Society include 95 270 
cases of colon cancer for 2016 and 39 220 rectal cancer cases.5  A retrospective 
cohort study evaluating the incidence patterns of colorectal cancer in the United 
States from 1974-2013 revealed that incidence rates of colon cancer increased 
by 1% to 2.4% annually since the mid-1980’s in adults age 20-39 years and by 
0.5% to 1.3% since the mid-1990’s in adults age 40-54 years.  In adults aged 55 
years and older, the incidence rates generally declined, suggesting a possible 
role for screening before the age of 50.6  This can be expected in other HICs 
(high income countries) in the next few years. 
 
There is a paucity of data for the incidence of colorectal cancer in Africa.  
Colorectal cancer incidence rates tripled in Algeria from 1986-89 to 1998-2002 
but remained stable in Mali, Uganda and Zimbabwe.3 An article detailing the 
Global Cancer Statistics showed that the lowest incidence rates are found in 
Africa when compared with Australia, New Zealand, Europe and North America.  
The highest rates in Africa were noted in Southern Africa (20.4 per 100 000 for 
males and 8.2 per 100 000 for females).7 The mortality rate in Southern Africa 
was 2.4 per 100 000 in men and 1.4 per 100 000 in women compared with those 
in developed countries (166.2 per 100 000 in men and 153.9 per 100 000 in 
women).1 Interestingly, the mortality-to-incidence rate ratio in Africa was high 
(0.89), where an MR:IR approaching one suggests limited survival, in comparison 
to North America (0.34). 3,4 Five-year survival rates are not available for Africa but 
those in America are high for early stage disease (74% for stage I, 65% for stage 
IIa and 52% for stage IIb) and decrease significantly for late stage disease (32% 
for stage IIc and 6% for stage IV).4 This is also not known in South Africa since 
the only document reporting on colorectal cancer is more than a decade old. 
 
Data from this National Cancer Registry detailed the incidence of histologically 
diagnosed cancer in South Africa from 1996-1997.  It reported a total of 854 and 
1047 new colorectal cancers in females in 1996 and 1997 respectively, which 
constituted 3.4% of all cancers in females. Similarly, a total of 894 and 1089 were 
diagnosed in males for the same periods, constituting 3.6% of all cancers in 
males.  Colorectal cancer therefore was the third leading cancer in females and 
the fifth leading cancer in males.8 However, this national registry is pathology-






It is well recognised that the adenoma-carcinoma sequence is the mechanism by 
which most colorectal malignancies arise.  It is a series of molecular and genetic 
alterations which result in histopathological effects.  These genetic changes 
accumulate over many years and include, the loss of the tumour suppressor 
gene, adenomatous polyposis coli (APC) and mutations in KRAS, PIK3CA and 
p53.  Dysplastic adenomas are the precursor lesions which can progress to 
adenocarcinoma.9,10 Early detection and removal can prevent rectal cancer.11 
 
There is controversy regarding the best surgical approach for early stage rectal 
cancer.  Radical surgery, which involves excision of the rectum with its lymphatic 
drainage, offers the best chance of cure, but at the cost of significant morbidity, 
mortality and cost.  Local tumour excision avoids the complications of major 
pelvic surgery.12 Transanal endoscopic operation (TEO), which equates to the 
technique of Transanal Endoscopic microsurgery (TEM) has been widely adopted 
as the treatment of choice for large rectal adenomas.  However, this has received 
minimal exposure in South Africa with the exception of two centres in Cape 
Town.   
 
1.2. History	
The excision of low rectal lesions has evolved from the transanal approach using 
open retraction, to an endoscopic approach. This includes several platforms 
using a rigid fibreoptic scope: TEM, TEO, TAMIS (transanal minimally invasive 
surgery).  A purely endoscopic approach is used for endoscopic mucosal 
resection and endoscopic submucosal dissection.13 
 
Transanal endoscopic operation owes its’ origin to TEM, transanal endoscopic 
microsurgery, a technique pioneered by the late Gerhard Buess in Germany the 
early 1980’s.  In collaboration with the Richard Wolff Company, he developed 
instruments to perform endoscopic surgery transanally to excise low and middle 
rectal adenomas and early cancers not amenable to colonoscopic or local 
resection.  The TEM system consists of four parts: the insufflating unit (which 
includes pressure monitoring, suction irrigation and provides the carbon dioxide), 
a removable face plate with ports, a rectoscope and a stereoscope allowing for 
magnification.  TEM is a very expensive, minimally invasive technique, requiring 
dedicated equipment and has a steep equipment learning curve, especially using 
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the insufflator which provides a stable pneumorectum, thus facilitating a 
magnified view of the intraluminal rectum.12–15  
 
In 1991, Karl Storz developed a similar system for transanal surgery which is 
cheaper, simpler and less complicated.  It consists of a rectoscope tube 4cm in 
diameter which allows the use of rectoscopes of varying lengths (7.5cm, 15cm, 
20cm).  Standard laparoscopic instruments and camera system can be used with 
this device.  A standard laparoscopic insufflator is used.14,16,17 Unlike TEO, the 
TEM system requires appropriate positioning of the patient to place the lesion at 
6 o’clock in the operating field.  This is not a requirement for the TEO device and 
represents a significant advantage over TEM.13,18 Another difference between the 
two is the three-dimensional vision offered by the TEM endoscopic procedure 
compared with a two-dimensional high definition vision offered by TEO.19 
 
The literature available for TEM ranges from retrospective reviews to randomised 
controlled trials and systematic reviews.  However, the literature for TEO 
specifically is quite sparse.  As a consequence, most of the data presented in this 
review has been acquired from research with TEM but these can rationally be 
extrapolated to TEO.   
 
A prospective randomized clinical trial comparing the effectiveness of TEM with 
TEO showed that no technical or clinical statistically significant differences were 
observed between the results obtained with the two systems.  There were no 
statistically significant differences between pre-operative (time taken to assemble 
equipment, surgical time, quality of pneumorectum) and post-operative variables 
(morbidity and mortality) or pathology results.  TEO was favoured with respect to 
a shorter time taken to assemble the equipment, surgical suture time and total 
operative time but it was not statistically significant.  TEM was found to be 
significantly more expensive than TEO.19 
 
1.3. 	TEM	compared	with	Transanal	Excision	
Transanal excision has been demonstrated to be adequate in premalignant 
lesions and in early stage rectal cancer of the mid- and lower rectum without poor 
prognostic features and imaging that demonstrates no lymph node involvement.12 
It is limited to tumours of less than 4cm in diameter located in the lower third of 
the rectum.  Lesions in the middle and upper rectum are inaccessible with this 
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technique.  Visualisation is often suboptimal resulting in inadequate and 
inaccurate oncological resection, higher rates of tumour fragmentation and higher 
recurrence rates.13 A systematic review and meta-analysis comparing TEM and 
transanal excision for the removal of rectal lesions found that TEM was 
oncologically superior.  While their postoperative complication rate was 
comparable (OR, 1.018; 95% CI, 0.658–1.575; p-0.937), TEM had a higher rate 
of negative resection margins (OR, 5.281; 95% CI, 3.201–8.712; p < 0.001) and a 
lower rate of specimen fragmentation (OR, 0.096; 95% CI, 0.044–0.209; p < 
0.001) and lesion recurrence (OR, 0.248; 95% CI, 0.154–0.401; p < 0.001).15 
 
A retrospective review comparing TEM and transanal excision found similar 
results: TEM had negative resection margins of 50% compared 88% after 
transanal excision.  Specimen fragmentation rate (1.4% and 23.8% respectively) 
and recurrence rate was much lower (3.2% for negative margins and 7.7% for 
positive margins for TEM and 0% and 59.6% for transanal excision.)20 
 
TEO was compared with transanal excision in a case-matched study with 
propensity score matching in an attempt to mitigate selection bias and increase 
the level of evidence of an observational non-randomised study.  This 
retrospective review also showed that the while the complication rates in the two 
groups were similar (TEO: 8.3% versus transanal excision: 11.1%, p-value 0.39), 
TEO had a higher negative resection margin rate (95.8% versus 86.1%, p-value 




Endoscopic submucosal dissection (ESD) is a technique which enables en bloc 
removal of epithelial lesions via endoscopic resection.  It was initially described 
as a non-operative method to manage gastric neoplasia.  With the evolution of 
techniques and equipment for ESD, the applications have expanded to included 
other parts of the gastrointestinal tract.22,23 ESD was compared to TEM for large 
non-invasive rectal lesions in a systematic review and meta-analysis.  While ESD 
was found to be safe and did not require general anaesthesia, TEM had a 
statistically significant higher rate of en bloc and R0 resection.  The en bloc 
resection rate was 87.8% in the ESD series and 98.7% in the TEM series and the 
R0 resection rate was 74.6% and 88.5% respectively.  The recurrence rate of 
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adenomas was 2.6% in the ESD series and 5.2% in the TEM series, but this 
could be accounted for by the much shorter follow-up period in the ESD series (6-
12 months) compared with an average follow-up period of 58.9 months.23 
 
1.5. 	TEM	compared	with	Endoscopic	Mucosal	Resection	
Endoscopic mucosal resection (EMR) is an endoscopic procedure which 
removes gastrointestinal lesions in the plane of the middle to deep submucosal 
layer, rather than the mucosal plane used in a standard polypectomy.  Similar to 
ESD, it provides en bloc resection specimens.24 A retrospective review of patients 
undergoing TEM or EMR for rectal adenomas greater than 2cm found that EMR 
for large rectal adenomas often results in a piecemeal resection with a higher risk 
of recurrence requiring re-intervention.  The authors investigated recurrence rates 
after a single intervention (early) and after permitting re-treatment for residual 
adenoma within 6 months (late).  Early recurrence rates were 10.2% in TEM and 
31% in EMR patients.  And late recurrence rates were 9.6% and 13.8% 
respectively.  Perioperative complication rates for TEM and EMR were 2% and 
6% and the post-operative complication rates were 24% and 13%.  The authors 
concluded that after a single intervention EMR was safer but less effective than 
TEM.  If retreatment of a residual adenoma was included within 6 months, TEM 
and EMR were equally effective.25 
 
The TREND Study, a randomised control trial comparing the clinical outcome and 
cost effectiveness of TEM and EMR for large rectal adenomas, was unable to 
demonstrate statistical non-inferiority of EMR with respect to recurrence rates.  
The recurrence rates were 15% and 11% for EMR and TEM respectively and 
complications occurred in 18% and 26%.  EMR was found to be more cost-
effective.  A concerning finding was the high rate of unexpected malignancies.  
Thirteen percent of the large adenomas harboured invasive disease and were 
excluded from the analysis resulting in a limitation of intention-to-treat analysis as 
acknowledged by the authors.26  
 
1.6. 	Indications	
Historically, the indications for TEM included benign lesions and invasive lesions 
in patients who were evaluated as being high risk of morbidity and mortality after 
radical resection, namely, anterior resection or abdominal perineal resection 
(APR).  They have now expanded to being an effective option in all rectal 
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tumours (adenomas, carcinoid, GISTs), including circumferential and proximal 
lesions, fistulous disease (high anorectal fistulas, rectourethral & rectovaginal 
fistulas), anastamotic strictures, correction of rectal prolapse and most 
pertinently, early stage rectal cancer.12,23,27 The indications discussed below 




The most common indication for TEM is benign, sessile low or middle rectal 
adenomas which cannot be removed colonoscopically or by transanal 
excision.13,18,28 A systematic review assessing the safety and efficacy of TEM in 3 
comparative studies and 55 case series found that complication rates ranged 
from 3 – 7% and local recurrence was 6% compared with 22% in the transanal 
excision group (with a median local recurrence of 5% for TEM).29 
 
TEM was initially indicated in mid-to low rectal adenomas defined as lesions of 
the extra-peritoneal rectum.  There is an increased risk of peritoneal perforation 
following TEM in upper and anterolateral rectal tumours.  In addition, it makes the 
maintenance of a stable pneumorectum difficult.30 In a retrospective review 
assessing the efficacy of TEM for lesions located in the upper rectum, defined as 
more than 10cm from the anal verge, the subgroup of patients with benign 
lesions (74 adenomas with or without high grade dysplasia) the local recurrence 
rate was 5.1% at a median follow-up of 8.7 years.  In this study, the rectal wall 
was perforated intra-operatively in 3 patients (3%).  After primary repair of the 
defect, 1 patient leaked post-operatively, requiring a formal anterior resection and 
diverting ileostomy.31 Khoury et al., concluded that TEM is feasible and may be 
safe in selected cases. In addition to expanding the indication for TEM to upper 
rectal tumours, its use has recently expanded to larger, circumferential 
adenomas. 
 
There is no universally accepted definition of a large adenoma with some 
reporting lesions over 2cm as large, while others only included circumferential 
lesions.  A systematic review and meta-analysis of endoscopic mucosal 
dissection (ESD) versus TEM for large (more than 2cm) non-invasive rectal 
lesions showed that TEM achieved a higher R0 resection rate (88.5% for TEM 
compared with 74.6% for ESD) but a higher recurrence rate (5.2% versus 
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2.6%).23 The TREND study, investigating lesions larger than 3 cm, reported 
recurrence rates of 15% and 11% for EMR and TEM respectively. Complications 
occurred in 18% and 26%. This study failed to demonstrate non-inferiority of 
EMR.26 
 
There were two retrospective reviews that defined lesions greater than 5cm.  In a 
European study (n =33) investigating giant rectal adenomas treated by TEM, a 
local recurrence rate of 12% and complication rate of 39.4% was demonstrated.  
The recurrence in all four patients (12%) were located in the lower third of the 
rectum and managed by conventional transanal excision.32 Similarly, another 
study describing a series of 25 patients with rectal lesions greater than 5cm 
excised by TEM, had a local recurrence rate of 10.9% after a median follow-up of 
2 years.33 Lastly, there is only one retrospective review that described the use of 
TEM for giant circumferential lesions (n=17). Four patients required endoscopic 
balloon dilatation for anal stenosis, one patient had post-operative bleeding 
requiring a second TEM and no patients developed faecal incontinence or urinary 
or sexual dysfunction.34 
 
1.6.2. Malignant	
The increase in the incidence of early rectal cancer can be attributed to the 
widespread introduction of screening programs.14,35 With the advancement in 
diagnostic, staging and treatment modalities, there is an increasing trend towards 
rectal-sparing treatment options including TEM and chemoradiotherapy.35   
   
The current standard of care for the treatment of rectal cancer, when sphincter 
preservation is possible, is TME (total mesorectal excision).  Despite the low 
recurrence and favourable long-term survival rates, it is associated with high 
rates of mortality and morbidity, including postoperative complications such as 
bleeding, anastomotic dehiscence, temporary or definitive colostomy and sexual 
or urinary dysfunction.  TEM provides a more elegant transanal solution with 
minimal morbidity but does not provide for lymph node sampling.14,18,35 
 
Early Rectal Cancer (T1) 
Previously, TEM was indicated for low risk, early cancers (pT1 N0) defined as 
tumours with favourable prognostic factors, that is, size less than 4 cm, well-
differentiated histology and an absence of vascular, lymphatic and perineural 
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invasion. The adherence to these criteria resulted in similar recurrence rates in 
TEM and radical resection but with lower morbidity and mortality.36  
 
In a prospective study aimed to determine the prognostic factors for recurrences 
and the need for reoperation in patients with pT1 carcinoma resected by TEM, 
the recurrence rates and 10-year cancer-free survival were reviewed.  The low 
risk group (R0 resection) had a recurrence rate of 6% and those in the high-risk 
group (unfavourable histology, R1, Rx, R1 < 1mm) had a recurrence rate of 39%.  
This high recurrence rate was reduced to 6% by re-operation.  Furthermore, the 
10-year cancer-free survival in the high-risk group was 93% after re-operation.  In 
patients with low risk pT1 rectal carcinomas, TEM can provide adequate 
oncological treatment.37 
 
In a randomized trial comparing TEM and anterior resection for early rectal 
carcinomas (T1), there were significant differences in length of hospital stay, 
blood loss, operating time and opiate analgesia, all favouring TEM.  While there 
was a difference between local recurrence and 5-year survival rates, it was not 
significant.  This study proved comparable rates of recurrence in TEM to the gold 
standard and showed a lower morbidity.38 
 
An evidenced-based review of the current indications, controversies and future 
perspectives of TEM in the management of rectal cancer, which includes 72 
studies, found that TEM is the ideal procedure for the local excision of selected 
early rectal cancers, offering a lower morbidity and mortality with no impairment 
of anorectal function and quality of life.  The long-term survival following TEM for 
low risk T1 cancers is similar to that achieved after TME.  In addition, the review 
showed that there is a role for full-thickness TEM in patients with intra-peritoneal 
rectal cancers with no increase in morbidity or mortality.35 
 
Risk factors for recurrence after TEM for rectal neoplasms were evaluated in a 
retrospective study.  The univariate analysis revealed that diameter, sm stage, pT 
stage, tumour grading, margin infiltration, and lymphovascular invasion were 
statistically significant.  The multivariate analysis indicated sm stage, pT stage, 
and tumour grading as independent predictors of recurrence.  Submucosal 
infiltration represented a significant risk factor for recurrences: 0% sm1, 16.7% 
sm2, and 30% sm3, with recurrence rates of 0% in pT1sm1 cancers and 22.7% 
in sm2-3 (p < 0.05).39 Submucosal involvement also relates to nodal involvement.  
 
 10 
In a review focussing on the inclusion criteria of early rectal cancer, nodal 
involvement in T1 cancer according to the grade of submucosal invasion was 
found to be 0-3.2% for sm1, 8-11% for sm2 and 12-25% for sm3.40 
 
 
Figure 1: Kikuchi classification of level of invasion of early invasive cancer 41  
 
T2 and T3 Rectal Cancer 
The indication for TEM has expanded.  There is a concern regarding the 
adequacy and efficacy of TEM for T2 and T3 rectal cancer because of high 
recurrence rates and the lack of a lymphadenectomy.18,35,38 The risk of lymph 
node involvement for T2 and T3 rectal adenocarcinomas is high.  The stage of 
the primary tumour determines the risk of lymph node involvement, with nodal 
positivity being 10-13% in T1 tumours and 17-22% in T2 tumours.42,43 
 
Tumour characteristics are also important in predicting lymph node metastases in 
rectal cancer.15 A population-based study investigating the risk factors for lymph 
node metastases found that a T2-stage, poor differentiation and vascular 
infiltration were significant risk factors.  The risk of lymph node metastases for T1 
and T2 rectal cancers was 65% and 78% respectively when associated with poor 
differentiation and vascular infiltration.  The analysis also indicated that high-risk 
T1 tumours had a greater probability of having lymph node metastases than low-
risk T2 tumours suggesting that curative resection for low-risk T2 tumours is a 
possibility.  Furthermore, the concept of local excision as a ‘macro biopsy’ with 




Another important factor is tumour location.  A retrospective review for sessile T1 
rectal cancer demonstrated that, in addition to lymphovascular invasion and sm3 
depth of invasion, tumours located in the lower third of the rectum are at high risk 
of lymph node metastasis.15,43    
 
Accurate pre-operative staging for rectal cancer is important when planning 
surgery, but despite advancements in imaging techniques, the pre-operative 
staging of nodal status is inadequate.44 Magnetic resonance imaging (MRI), 
endorectal ultrasound (ERUS) and computed tomography (CT) are used for the 
pre-operative assessment of a patient being considered for TEM.  While ERUS is 
able to differentiate between the layers of the rectal wall and thus determine the 
T-stage, and is the most accurate for early tumour invasion of the rectal wall 
when reported by experts, it is not readily available, is operator-dependent and 
has a limited depth of penetration to be used for nodal staging.45,46 For MRI, the 
accuracy of T-staging ranges between 66% and 91% and N-staging between 
65% and 88%.47 
 
A few studies have found that there was no statistically significant difference in 5 
year survival rates in patients with T2 lesions but there was an increased risk of 
local recurrence.18 A prospective study, which sought to determine the value of 
local excision for T2 rectal carcinomas, prognostic factors and the need for re-
operation (repeat TEM), found that of their 649 patients, 44 had a T2 lesion.  An 
immediate re-operation was recommended but 24 patients declined further 
surgery or were not fit for surgery due to comorbidities.  The local recurrence 
rates following local R0 resection of the low risk T2 tumours were 29%.  Patients 
with unfavourable criteria, namely, involved resection margins (R1), a distance of 
tumour to the resection margin of less than 1mm (R<1mm), tumour fragmentation 
or an unclear resection margin (Rx), poor histological tumour grade (G3-4) and 
lymphovascular invasion, developed recurrences in 50%.  But after salvage 
surgery, that is, immediate re-operation, the local recurrence was reduced to 7%.  




A retrospective review of patients who had a repeat TEM, for involved resection 
margins of locally excised cancer or benign local recurrence, demonstrated 
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favourable short-term outcomes similar to those following a primary TEM.  There 
was no statistically significant difference between the mean operative times and 
intra- and post-operative complication rates.  Furthermore, a repeat TEM did not 
impair anal sphincter function.49 Similarly, a prospective study evaluated the 
safety and efficacy of repeat TEM after R1 endoscopic resection or local 
recurrence of early rectal cancer after operative endoscopy and found that a 
repeat TEM can be used as diagnostic procedure and a curative treatment 




TEM following Neoadjuvant Therapy 
In a select group of patients with low rectal cancer, neoadjuvant therapy 
combined with TEM may be an alternative treatment option to TME.  Neoadjuvant 
therapy may improve tumour resectability, allow for sphincter-preserving 
procedures and better local control of the disease.35,51 A prospective randomised 
trial compared TEM and laparoscopic TME in patients with small, low rectal 
cancer following neoadjuvant chemoradiotherapy.  The recurrence rates were 
similar in the two groups and there was no statistically significant difference in 
disease-free survival.51 An evidence-based review of TEM in the management of 
rectal cancer, demonstrated that adequate oncological results could be achieved 
in highly selected T2 N0 rectal cancers but recommended that this be proposed 
in the setting of a clinical trial until the results are verified by more robust 
studies.35 
 
Adjuvant Therapy following TEM 
A meta-analysis of oncological outcomes after local excision of unfavourable pT1 
and pT2 rectal cancer requiring adjuvant chemoradiotherapy or completion 
surgery found that the local recurrence rate was higher in patients with locally 
excised pT1/pT2 rectal cancer treated by chemoradiotherapy than in patients 
who had a completion TME.  There were a number of limitations in this meta-
analysis.  The two groups were not directly comparable.  Radiotherapy schedules 
were not identical among the cohorts and some patients received radiotherapy 
alone.  The authors concluded that the standard of care after local excision or 
endoscopic resection of high-risk pT1 and pT2 rectal cancer remains a 
completion TME, but that in selected patients with intensive follow-up and early 
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TEM or TEO is a well-established technique which is indicated as a definitive 
treatment for benign adenomas and pT1sm1 carcinomas. T1 sm2-3 and T2 
lesions should only be included in prospective trials after having been thoroughly 
staged pre-operatively.  With advancing technology and surgical expertise, the 
indications are expanding.  In South Africa, there is no data regarding the 
experience of the outcomes of TEO for benign rectal adenomas and early rectal 
cancer.  This research will assist in identifying whether TEO is applicable to low- 
and middle-income countries (LMIC) for less invasive management of benign 







































The aim of this study was to evaluate TEO (the simpler and more affordable 
platform of the two) in an academic referral centre in South Africa by describing 
the dimensions and anatomical parameters of specimens resected and using this 
to investigate whether any of these are predictive of recurrence, and to evaluate 
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TITLE: Transanal Endoscopic Operation (TEO) – Local experience in a 
South African Setting 
 
Background 
It is well recognised that the adenoma-carcinoma sequence is the mechanism by 
which most colorectal malignancies arise.  Dysplastic adenomas are the 
precursor lesions which can progress to adenocarcinoma and premalignant 
sessile villous adenomas represent a particular challenge.  Their early detection 
and removal can prevent rectal cancer.  Local excision of low rectal tumors has 
become increasingly popular as technical advancement has rendered it easier 
and more effective.  Local tumour excision avoids the complications of radical 
surgery.  Transanal endoscopic operation (TEO) and Transanal endoscopic 
microsurgery (TEM) are two equivalent techniques that have been widely 
adopted as the treatments of choice for large rectal adenomas and selected 
rectal cancers but has been under-employed in South Africa. 
 
The aim of this study was to evaluate TEO (the simpler and more affordable 
platform of the two) by describing the dimensions and anatomical parameters of 
specimens resected and using this to investigate whether any of these are 
predictive of recurrence, and to evaluate the incidence of complications of this 
less radical technique. 
 
Methods 
In this single surgeon study, data was collected from pre-existing patient files 
(paper and electronic) during the first half of the time period and during the 
second half, was prospectively entered into a database.  It includes all patients 
undergoing resection of benign and malignant rectal tumours by TEO at a private 
(Kingsbury Hospital) and public health institution (Groote Schuur Hospital) from 
January 2009 – May 2017.  Electronic records, including operation notes, 
histology and radiology were reviewed. 
 
Results 
Data was collected from January 2009 to May 2017.  There were 110 patients in 
this study of which 87 (79.1%) were benign.  There were 11 (12%) recurrences in 
this group.  In the malignant group, there were 5 (21%) recurrences.  The median 
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tumour length was 4.5cm (IQR 2.5) and median tumour area was 16cm2 (IQR 
20.11).   
For benign lesions, there was a significant difference in recurrence in patients 
presenting with incontinence (χ2 8.21, p-value<0.01, OR 16.7 (1.37-202.7)), 
lesions with involved surgical margins (χ2 6.29 p-value 0.01, OR 6.75 (95% CI 
1.02 - 35.7)) and circumferential tumours (χ2 6.31 p-value 0.04, 6.5 (1.17-36.3)).  
The multinomial logistic regression model in this series for benign lesions 
revealed that only incontinence and involved surgical margins were independent 
predictors of recurrence.  Complications occurred in 21 (19.1%) patients.  A 
multinomial regression model showed that circumferential lesions, length of the 
tumour, and malignancy were predictive of complications.  
 
Conclusion 
This study constitutes the only report of TEO or TEM from a low- or middle-
income country (LMIC).  Both the recurrence and complication rates are in 
keeping with international results demonstrating the potential for this procedure to 
be safe and feasible in this LMIC setting, which will reduce the need for 
expensive, highly morbid radical surgery for benign and malignant disease.  The 
recommendation is for a wider introduction of TEO in South Africa and other 
























Colorectal cancer is one of the leading causes of death in developed countries 
and found to be the third most common cancer in men and third most common 
cancer worldwide.1–3  
 
It is well recognised that the adenoma-carcinoma sequence is the mechanism by 
which most colorectal malignancies arise.4,5 Dysplastic adenomas are the 
precursor lesions which can progress to adenocarcinoma.  Early detection and 
removal can prevent rectal cancer.6 
 
Transanal endoscopic operation (TEO), which equates to the technique of 
Transanal microsurgery (TEM), has been widely adopted as the treatment of 
choice for large rectal adenomas, but has been little practised in South Africa with 
the exception of two centres in Cape Town, which attracted a large number of 
tertiary referral patients. 
 
The excision of rectal lesions has evolved from invasive conventional rectal 
resection to include transanal excision, endoscopic mucosal resection, 
endoscopic submucosal dissection and in the last 30 years, TEM and TEO.7 
 
The advantages of TEO over standard transanal excision include better exposure 
of the rectum, with lower recurrence and complication rates.8 
 
There is no data regarding the South African experience of outcomes of TEO for 
benign rectal adenomas and early rectal cancer. 
 
The aim of this study was to evaluate TEO (the simpler and more affordable 
platform of the two) by describing the dimensions and anatomical parameters of 
specimens resected and using this to investigate whether any of these are 
predictive of recurrence, and to evaluate the incidence of complications of this 









This is a mixed design study using both retrospective and prospectively collected 
data and evaluates the outcomes of a single surgeon case series from both a private 
and an academic hospital. 
 
This research project includes patients who presented with benign and malignant 
rectal cancer at a private (Kingsbury Hospital) and public health institution (Groote 
Schuur Hospital) undergoing a Transanal Endoscopic Operation (TEO) from January 
2009 to May 2017, comprising 110 patients.   
 
Clinical records, including operation notes, histology and radiology were interrogated 
for these patients.  The variables which were collected in the database include: 
symptoms, tumour length (defined as the largest diameter), tumour surface area, 
height of tumour, extent of circumferential involvement, histology (pre-operative and 
final), details of the procedure, length of stay, complications, recurrence and time to 
recurrence.  Also assessed was the microscopic margin and surgeon assessed 
margin (endoscopic or surgical).  Although margins were usually assessed 
endoscopically, lesions extending into the anal canal required an initial open 
approach to mobilise the lower anal margin.  In this instance, the surgeon recorded 
the margin as a surgical margin.  Data was collected retrospectively from 2009 to 
2013 and prospectively from 2014 to May 2017. 
 
Data	collection	
For the private sector patients, data was extracted from the online database, 
Medscreen, an in-house purpose designed practice database, on which each 
patient’s notes, endoscopic photographs, radiology, histology and operative reports 
are recorded.  Pathcare Laboratories performed the histological analysis.  In the 
public sector, data was collected from patient folders, the operative reports from an 
electronic folder and histological results from the National Health Laboratory Service.   
 
The size of the lesions was divided into small (less than 2cm), large (2 - 4cm) and 
giant, (4cm or greater).  This classification was used in the absence of any uniform 





All patients who underwent a TEO during the study period for both benign and 
malignant disease were included.  All patients underwent colonoscopy and pre-
operative biopsies prior to surgery.  Many tertiary referral patients had these done 
prior to initial consultation. All patients underwent examination and at least a 
sigmoidoscopy by the surgeon (RJB) where the height of the lesion would be 
assessed.  Biopsy was repeated as necessary.   
 
Patients with a malignant biopsy result underwent staging pelvic MRI to evaluate 
their suitability for local excision. After its use early in the series, ERUS (endorectal 




All patients were prepared with a full bowel prep the previous evening.  They were all 
consented for the possibility of intentional or inadvertent peritoneal entry, possibly 
requiring immediate corrective abdominal surgery, including the possibility of a 
stoma.  Patients were not catheterised unless the procedure was unusually long or 
had been complicated.  General anaesthesia was invariably used except where it 
was not considered safe by the anaesthetist, in which rare circumstance a spinal 
block was used.  The patient was positioned in Lloyd-Davies.  After a four quadrant 
anal block with bupivacaine infiltration, a slow and gradual anal stretch was 
undertaken, until the proctoscope could be passed without force.  The lesion was 
resected usually using ultrasonic shears (Harmonic® Ultrasonic HD 1000i Shears, 
Ethicon Endosurgery) or sometimes monopolar diathermy.  Defects were closed 
selectively using a V-Loc suture (V-LocTM wound closure device, Medtronic/Covidien) 
after the tumour bed had been copiously irrigated.   
 
Where the lesion extended into the anal canal, preventing an air seal at its lower 
margin, the procedure was initiated as an open dissection with anal retraction. Once 
sufficient sphincter had been cleared to allow a seal, the proctoscope was placed 
and the procedure completed endoscopically.  Every effort was made to excise the 
lesion as a single intact specimen, but for very large carpet lesions it was sometimes 
necessary to do the resection piecemeal in order to maintain adequate visibility. 
Where necessary, the proximal mucosal margin was sutured to the anoderm to 
restore the muco-cutaneous bridge and avoid stricturing. Where the peritoneum was 
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breached, a full thickness closure was undertaken.  After this, laparoscopy was 
sometimes performed to ensure complete closure and perform an air test to exclude 
a leak.  All specimens were submitted pinned on a corkboard. 
	
Statistical	Analysis	
Microsoft Excel 2017 (Redmond, Washington, USA) and Mathematica Version 11 
(Champaign, Illinois, USA) were used for data collection and analysis.  
 
Research variables were categorised as: nominal categorical, ordinal categorical and 
continuous numerical.  The continuous numerical variables were analysed for the 
assumptions of the use of parametric tests by way of the Shapiro-Wilke test and 
quantile-quantile plots.  The distribution of continuous numerical variables that failed 
these assumptions were analysed using non-parametric tests.  The Student’s t-test 
for independent groups, assuming equal variance was used as the parametric test 
and the Mann-Whitney-U test was the non-parametric test used.  Point estimates and 
measures of dispersion for parametric tests were expressed as mean and standard 
deviation and for non-parametric tests were expressed as median and interquartile 
range, except for age, where dispersion was expressed as a range. 
 
Proportions for categorical variables were examined using the chi-squared test for 
independence. 
 
A multinomial regression model was created to predict recurrence. 
 
An alpha value of 0.05 was used to indicate significance and a confidence level of 
















One-hundred and ten patients were included in the review of which were 57 male 
(51.8%).  The median age was 67 years (range 24 – 92).  Ninety-three (84.5%) 
patients were referred from elsewhere with a confirmed diagnosis.   Thirty-four 
(30.9%) presented with rectal bleeding, 28 (25.4%) with a change in bowel habit and 
six (5.5%) with incontinence.  At final histology there were 47 adenomas with low 
grade dysplasia (42.7%), 33 with high grade dysplasia (30%), 23 with 
adenocarcinoma (20.9%) and one traditional serrated adenoma (0.91%).  The rest of 
the patients had a fibrous scar or no disease (6 patients, 5.45%).  The 
adenocarcinomas were comprised of 14 T1 tumours (60.9%), seven T2 tumours 
(30.4%) and two T3 (8.69%).  In total, there were 87 (79.1%) benign lesions and 23 
(20.9%) malignant lesions.  The median duration of follow-up was 15 months (0-91). 
 
The tumour dimensions were evaluated in terms of length and area.  The median 
tumour length was 4.5cm (IQR 2.5) and the median tumour area was 16cm2 (IQR 
20.11).  The median length was 4.5cm (IQR 2.5) for benign lesions and 5cm (IQR 
2.4cm) for malignant lesions.  The median tumour area was 15.8cm2 (IQR 19.6) for 
benign lesions and 18cm2 (IQR 19.4) for malignant lesions. (Table 1) 
 
Table 1: Length and Area for Benign and Malignant Specimens 
 Benign (IQR) Malignant (IQR) 
Median Length 4.5cm (2.5) 5cm (2.4) 
Median Area 15.8cm2 (19.6) 18cm2 (19.4) 
Total 87 23 
Length in cm and area in cm2 
 
 
The tumour involved less than half the circumference in 72 patients (65.5%), more 
than half the circumference in 31 patients (28.2%) and it was completely 
circumferential in 7 patients (6.36%).  Size was also categorized into small, large and 
giant. (Table 2) 
 
Table 2: Overall size and comparison of benign and malignant 
 Benign Malignant Total 
Small 2 (66.67%) 1 (33.3%) 3 (2.7%) 
Large 27 (79.4%) 7 (20.6%) 34 (30.9%) 
Giant 58 (79.5%) 15 (20.5%) 73 (66.3%) 




Over 90% of patients with benign polyps had clear endoscopic or surgical margins.  
But there was microscopic involvement in 16 (18.4%).  Similarly, with indeterminate 
lesions, there was a disparity between the margins assessed as being indeterminate 
by the surgeon (1.2%) and the pathologist (12.6%). (Table 3)  There were similar 
proportions in the surgically involved margins between benign and malignant lesions 
(χ2 1.98, p-value 0.37).  There were also similar proportions in the microscopically 
involved margins between benign and malignant lesions (χ2 0.35 p-value 0.84). 
(Table 3) 
 
Table 3: Surgical and histological margins for benign and malignant lesions 
Surgical Margins Benign Malignant 
   
Clear (R0) 80 (91.9%) 23 (100%) 
Involved (R1) 6 (6.9%) 0 (0%) 
Indeterminate (Rx) 1 (1.2%) 0 (0%) 
   
Microscopic Margins   
   
Clear (R0) 60 (69%) 16 (69.6%) 
Involved (R1) 16 (18.4%) 5 (21.7%) 
Indeterminate (Rx) 
 




Height of the lower border of the tumour was measured in centimeters from the 
anorectal ring.  While some of these lesions extended below the anorectal ring and 
were given a minus value, the median height was 3cm (IQR 5).  There was no 
statistically significant difference in the height of the tumour in the 3 macroscopic 
margin groups (p-value 0.28).  Similarly, in the 3 microscopic margin groups (p-value 











The median time to recurrence was 14.3 months (IQR 28.9).  Management of 
patients who developed a recurrence included: endoscopic excision (11), endoscopic 
ablation (1), repeat TEO (1), EMR (1), laparotomy (1) and no further intervention (1). 
 
Benign Lesions 
In the cohort of patients with benign lesions, 46 (52.9%) were male and 41 (47.1%) 
female.  The median age was 64.8 years (range 35 - 92). 
 
Of the 87 patients with benign lesions, 11 patients developed a recurrence (12.6%).   
 
A number of variables were compared in patients who developed recurrence and 
those who did not.  These variables were: gender, age, presenting symptoms 
(bleeding, change in bowel habit, incontinence), height, lesions more than a half of 
the circumference, circumferential lesions, size of tumour (in mm), piecemeal 
dissection, the involved surgical margins, involved histological margins and 
complications.  A multinomial logistic regression model was constructed to predict 
recurrence using these variables. 
 
There was a statistically significant recurrence rate among patients who presented 
with incontinence (χ2 8.21, p-value<0.01), those with circumferential lesions (χ2 6.44, 
p-value 0.04) and those in whom the surgical margins were involved (χ2 6.4, p-value 
0.04, odds ratio 5.19 (95% CI 1.04 – 25.9)) (Table 4) 
 
Of these single variable logistic regression evaluations, the variables that had a p-
value <0.2 were included: Bleeding, incontinence, Height, circumferential lesions, 
piecemeal, involved surgical margins and complications. 
 
Only incontinence (p-value 0.01, OR 37.66 (CI 2.14 - 664)) and involved surgical 
margins (p-value 0.02, OR 12.9 (CI 1.47 -113) significantly increased the odds of 









Table 4: Single variable logistic regression to determine predictors of local recurrence for 
benign lesions 
 
Variables Recurrence No Recurrence Chi2, p-value OR (95% CI) 
     
     
Gender   χ2 1.48, p-value 0.24 0.46 (0.12-1.71) 
M 34 42   
F 7 4   
     
     
Age 61.1 yrs  
(46-84) 
65.4 yrs  
(35-92) 
p-value 0.22 0.96 (0.91-1.03) 
Symptoms     
Bleeding 5 17 χ2 2.71, p-value 0.1 2.89 (0.78-10.65) 
No bleeding 6 59   
     
Change in bowel 
habit 
4 18 χ2 0.82, p-value 0.37 1.84 (0.48-7.01) 
No change in 
bowel habit 
7 58   
     
Incontinence 2 1 χ2 8.21, p-value<0.01 16.7 (1.37-202.7) 
No incontinence 9 75   
     
     
Height 3 cm (IQR 5) 5.5 cm (IQR 6) p-value 0.19 0.88 (0.72-1.07) 
     
     
Circumference   χ2 6.31 p-value 0.04  
Less than half 6 52   
More than half 2 40  0.87 (0.16-4.66) 
Circumferential 3 4  6.5 (1.17-36.3) 
     
     
Tumour length 34mm (IQR 16mm) 34mm (IQR20.8) p-value 0.66 1 (0.98-1.04) 
     
     
Piecemeal 3 8 χ2 2.44 p-value 0.12 3.19 (0.87-14.5) 
Not piecemeal 8 68   
     
     
Surgical Margins   χ2 6.29 p-value 0.01 6.75 (1.02-35.7) 
Clear 8 72   
Involved 3 4   
     
     
Histological 
Margins 
  χ2 1.22 p-value 0.27 2.05 (0.57-7.4) 
Clear 6 54   
Involved 5 22   
     
     
Complications 4 10 χ2 3.83 p-value 0.05 3.77 (0.93 -15.2) 
No complications 7 66   
     











On final histology, only 23 lesions were malignant.  Similar variables were used in the 
analysis.  None of these could be shown to be predictors of recurrence. (Table 5) 
 
Table 5: Single variable logistic regression to determine predictors of local recurrence for 
malignant lesions 
 
 Recurrence No Recurrence Chi2, p-value OR (95% CI) 
     
     
Gender   χ2 2.65, p-value 0.1 6.29 (0.58-68.4) 
M 1 11   
F 4 7   
     
     
Age 62.2yr (24-90) 69.7 (47-91) p-value 0.35 0.97 (0.91-1.03) 
     
     
Symptoms     
Bleeding 2 10 χ2 0.38, p-0.54 value 0.53 (0.07-4) 
No bleeding 3 8   
     
Change in bowel 
habit 
2 4 χ2 0.05, p-value 0.82 2.33 (0.28-19.2) 
No change in bowel 
habit 
3 14   
     
Incontinence 1 2 χ2 0.05, p-value <0.82 2 (0.14-28) 
No incontinence 4 16   
     
     
Height 3.8 cm (SD1.3) 4.22cm (3.19SD) p-value 0.78 
 
0.95 (0.66-1.36) 
     
     
Circumference   χ2 4.48 p-value 0.03  
Less than half 1 13   
More than half 4 5  10.4 (0.92-117) 
Circumferential 0 0   
     
     
Tumour length 27.4 mm (SD24) 26.7mm (SD 17) p-value 0.97 1 (0.95-1.06) 
     
     
Piecemeal 1 0 χ2 0.49 p-value 0.48  
Not piecemeal 4 18   
     
     
Surgical Margins     
Clear 5 18   
Involved 0 0   
     
     
Histological Margins   χ2 <0.01 p-value 0.98 1.7 (0.22-13.7) 
Clear 3 13   
Involved 2 5   
     
     
Complications 3 4 χ2 1.16 p-value 0.28 5.25 (0.64 -43.1) 
No complications 2 14   




Eighty-nine (80.9%) patients did not have complications.  Complications occurred in 
21 (19.1%) patients and were distributed as follows: Five (4.5%) had a perforation 
(one of whom had an anterior resection and one had a Hartmann’s), three had an 
immediate laparoscopy (all of whom had no defect noted after suture closing during 
TEO), six patients (2.7%) had asymptomatic mild anal or rectal strictures, three 
patients had post-operative bleeding (one of whom required an EUA and cautery and 
one of whom required an EUA and haemostatic rectal sponge and transfusion), three 
(2.7%) had urinary retention and one patient developed a rectovaginal fistula which 
required a defunctioning stoma until spontaneous healing whereupon the stoma was 
closed uneventfully.  One patient reacted adversely to anaesthesia, with a mild 
cholinergic syndrome which resolved promptly (0.91%), one had mild faecal 
incontinence which resolved within 3 months (0.91%) and two patients required re-
look laparotomies. 
 
There was no significant difference between the proportions of complications 
between patients with benign and malignant polyps (χ2 2.42, p-value 0.12). (Table 6) 
 
Table 6: Summation of complications for benign and malignant polyps 
 
 Complications No complications 
Benign 14 (16.1%) 73 (83.9%) 
Malignant 7 (30.4%) 16 (69.6%) 
 
Patients with complications had a median carpet length of 5.5cm (IQR 2.5) compared 
to those without complications who had a median length of 4.4cm (IQR 2.1) (p-value 
0.01).  There was no difference in complications between those with small, large and 
giant lesions (χ2 4.49 p-value 0.11).  There was a significant difference between 
tumour circumference and complications (χ2 23.3, p-value < 0.01). (Table 7) 
 
Table 7: Complications in relation to size and circumferential involvement 
 
 Complications (%) No complications (%) Total 
Small 0  (0.0%) 3  (100%) 3 
Large 3  (8.8%) 31 (91.2%) 34 
Giant 18 (32.7%) 55 (75.3%) 73 
    
Less than half 8 (11.1%) 64  (88.9%) 72 
More than half 7 (22.6%) 24  (77.4%) 31 




The median height of the lesions in patients who had a complication and in those 
with no complications was both 3 cm (IQR 7). 
 
A multinomial logistic regression model was constructed to predict complications. 
The predictive variables chosen for assessing complications were: Lesions more 
than half the circumference, circumferential lesions, piecemeal dissection, involved 
endoscopic or surgical margins, involved microscopic margins, tumour length, width, 
height and the presence of a malignancy. 
 
The presence of a circumferential lesion significantly increased the odds of a 
complication compared to a lesion that was less than a half of the circumference (p-
value <0.01, OR 1.07 (CI 3.2 - 1196)).  Length (p-value 0.04, OR 1.06 (CI 1 – 1.12) 
and malignancy (p-value < 0.01, OR 5.8 (CI 1.55 – 22.4) were similarly a predictive 
of the development of a complication  
	
Correlation	of	biopsy	with	final	histology	
A comparison between the histology of the pre-operative biopsy and the post-
operative specimen revealed that the histology was the same in only 60 patients 
(54.5%).  This results in a sensitivity of 41%, a specificity of 93.2%, a positive 
predictive value of 60% and a negative predictive value of 86.3%. (Table 8) 
 
Table 8: The Comparison of Pre-operative and Final Histology 
  Final Histology 
  Benign Malignant 
Pre-operative 
biopsy 
Benign 82 13 
Malignant 6 9 
 
Mortality	
Ten (9.1%) patients in this series died but their deaths were unrelated to the 








Historically, the indications for TEO and TEM included benign polyps and invasive 
lesions in patients who were evaluated as being unsuitable for radical resection.  
With increasing experience, circumferential and more proximal polyps are now 
managed with TEO.  There are now reports of TEO being used in the management 
of fistulous disease (high anorectal fistulas, rectourethral & rectovaginal fistulas).  
Other more exotic indications in high volume centres included GISTs, anastomotic 
strictures, correction of rectal prolapse and most pertinently, early stage rectal 
cancer.9–11 
 
The aim of this study was to evaluate TEO (the simpler and more affordable platform 
of the two) by describing the dimensions and anatomical parameters of specimens 
resected and using this to investigate whether any of these are predictive of 
recurrence, and to evaluate the incidence of complications of this less radical 
technique. 
 
Nearly 80% of specimens were benign but a comparison between the histology of 
the pre-operative biopsy and the final histology revealed very poor correlation with a 
negative predictive value of 86.3%.  This is most likely due to sampling error, 
because a small malignant focus was often found within the much larger villous 
carpet, so that the pre-operative biopsies of the carpet could easily miss the 
cancerous component.  In this study, there were unexpected malignancies in 13.68% 
of lesions.  This is remarkably consistent with the findings in the 2017 TREND study, 
the first randomised controlled trial comparing the clinical outcomes and cost 
effectiveness of TEM and EMR for large rectal adenomas.12 
 
Nearly 15% of patients developed recurrence.  The 12.6% recurrence rate in the 
benign polyp cohort is consistent with other series where recurrence rates ranged 
from 5.1 – 15.8%.10,13–17 In this series, incontinence as a presenting symptom, 
circumferential lesions and involved surgical margins were significant in patients who 
developed recurrence.  While height was not significant, patients with lower lesions 
extending to the anal canal had a higher incidence of recurrence.  The failure to 
achieve significance is likely a type II error, that is, failure to detect an effect that is 
present, usually resulting from insufficient sample size.  These recurrences are likely 
to result from the closer distal margins in these anal canal lesions used to prevent 
damage to the anal sphincters.  The border of these tumours would commonly be 
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involved or within 1mm of the cauterised margin.  This diathermy artefact could 
explain the discrepancy between the surgeon recording a clear margin and the 
pathologist reporting it as involved or indeterminate. 
 
A multinomial analysis of the risk of recurrence in a retrospective study aiming to 
identify predictor variables for recurrence after TEM found that only involved 
microscopic margins were significant.17 The multinomial logistic regression model in 
this series for benign lesions revealed that only incontinence and involved surgical 
margins were significant predictors of recurrence.  The correlation with recurrence 
must be explained by the size and distal location of the lesion.  Larger lower lesions 
are most likely to produce larger volumes of mucus close to the sphincter, thus 
causing a mucous leak.  These large low lesions are sometimes chronically 
prolapsed, also rendering the patient wet and complaining of incontinence. 
 
Hypotheses for recurrence include incomplete removal of the lesion and the concept 
of instability of the rectal mucosa and field changes, where a tendency to dysplasia 
and villous formation in the adjacent rectal mucosa remains despite the lesion being 
excised.  This was supported in several cases where polyp ‘recurrence’ was situated 
several centimetres from the tumour scar.  Another explanation might be exfoliation 
and re-implantation of viable tumour cells.18–20 
 
A positive margin is a strong predictor of recurrence, and large adenomas have a 
higher rate of recurrence.17 In this study, over 90% of patients with benign polyps had 
clear endoscopic or surgical margins.  However, of these, there was microscopic 
involvement in 18.4%.  Similarly, in lesions with indeterminate margins, there was a 
disparity between the margins assessed as being indeterminate by the surgeon 
(1.2%) and the pathologist (12.6%).  This disparity was most often seen in the larger 
lesion and circumferential lesions which may have been removed piecemeal.  While 
enormous care was taken by the surgeon to pin all completely excised specimens to 
a corkboard in an attempt to preserve the margin between normal tissue and tumour, 
specimen handling remains a possible contributory factor. 
 
In the benign cohort, 31% were large lesions (2 - 4cm) and 67% were giant lesions (> 
4cm).  While this is comparable with the international literature where the median 
sizes ranged from 3–5.7cm,10,13–16 it reflects severe under-reporting of the size as the 
measurements were taken after being placed in formalin which causes shrinkage.  
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One study, describing giant circumferential adenomas, had a median size of 7cm (3-
10 cm) and a recurrence rate of 23.5%.11  
 
 
Complications, in this series, occurred in 21 (19.1%) patients and are comparable 
with the literature where the complication rate ranged from 0% to 35.7%.10,11,13–15,21–24 
Lesion size and circumferential involvement were statistically significant when 
comparing patients who developed complications to those who did not.  However, 
serious complications requiring laparoscopy and stoma formation correlated with 
higher lesions, especially when situated anteriorly.  A multinomial regression model 
demonstrated that the presence of a circumferential lesion, the length of the lesion 
and malignancy were predictive of a complication.  
 
Limitations	
There are a number of limitations in this study which should be addressed in future 
research.  While this is a substantial series of TEO procedures, nevertheless the 
patient numbers are insufficient to determine significant outcomes.  Another limitation 
was the possible under-reporting of the size of the lesions.  The specimen 
measurements were taken after fixation with formalin that causes shrinkage of tissue. 
 
Conclusion	
This study constitutes the only report of TEO or TEM from a low- or middle-income 
country (LMIC).  Both the recurrence and complication rates are in keeping with 
international results demonstrating the potential for this procedure to be safe and 
feasible in this LMIC setting, which will reduce the need for expensive, highly morbid 
radical surgery for benign and malignant disease.  The recommendation is for a 
wider introduction of TEO in South Africa and other LMIC countries with the provision 
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BJS publishes illustrations in the print issue that are used as the basis for a surgical 
quiz. We consider single surgical images in colour that are of educational value to 
surgeons. 
Specifications: 
All illustrations must be in colour and of a high quality (>400dpi, preferably TIFF or 
EPS files); they must not have been published previously. Snapshots should be 
accompanied by a short question that might be general (e.g. what is this condition, 
and how should it be treated?), or multiple choice. The authors must also provide the 
answers to the quiz using text of no more than 100 words. Images of patients should 
be accompanied by a signed consent form available here. 
Snapshots in Surgery should be submitted online at http://mc.manuscriptcentral.com/bjs. 
Please note that there are many mandatory sections during submission that are not 
relevant to Snapshots in Surgery. Please mark these as ‘N/A’ in the ScholarOne 
submission. 
To view all previous Snapshots in Surgery please click on Clinical Library and go to 
Images. 
BJS works together with Wiley’s Open Access Journal, Clinical Case Reports, to 
enable rapid publication of good quality snapshots that the Editors are unable to 
accept for publication in BJS. Authors of snapshots rejected by BJS will be offered 
the option of having their snapshot, along with any related peer reviews, 
automatically transferred for consideration by the Clinical Case Reports editorial 
team. Authors will not need to reformat the snapshot at this stage, and publication 
decisions will be made a short time after the transfer takes place. Clinical Case 
Reports will consider case reports, clinical images and procedural videos from every 
clinical discipline including Medicine, Nursing, Dentistry, and Veterinary Science. 
Clinical Case Reports is a Wiley Open Access journal and article publication fees 
apply. For more information please go to www.clinicalcasesjournal.com. 
 
h) Your comments 
The Editors welcome topical comment from readers relating to articles published in 
the Journal. Correspondence should be submitted via the abstract page of the article 
after registration on this website. All letters will be reviewed and, if approved, appear 
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on the website. Comments must be no more than 250 words in length, including no 
more than five references. Original data will not be published in the comments 
section. 
 
3. Preparation of manuscripts 
BJS subscribes to the policy of uniform requirements for manuscripts; this facilitates 
resubmission of papers to journals without extensive recasting. Authors are advised to 
consult the Uniform Requirements for Manuscripts Submitted to Biomedical 
Journals1. BJS accepts the criteria for authorship proposed in the ICMJE1,11 and 




BJS seeks to minimize the risk of gratuitous authorship by limiting the number of 
authors listed in an article. BJS holds the view that in the context of surgical 
publishing, most articles are unlikely to involve significant contributions from more 
than ten authors. For our full authorship policy and information on how multiple 
authorship should be handled please 
click http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-
of-authors-and-contributors.html. 
For articles with more than ten authors, BJS requests that this form be completed and 
submitted alongside the manuscript. Please ensure that all conditions listed in the 
form are met and that all authors sign it. 
For research papers, authorship should be decided at the launch of the study. The 
authorship credit should be based on 1) substantial contributions to conception and 
design, or acquisition of data, or analysis and interpretation of data; 2) drafting the 
article or revising it critically for important intellectual content; and 3) final approval 
of the version to be published. Authors should meet conditions 1, 2 and 31. 
Contributors who do not qualify as authors should be listed and their particular 
contribution described in the Acknowledgements section of the article. On submission 
of the article, the corresponding author will be asked to confirm how all individuals 
listed as authors meet the appropriate authorship criteria, that no-one who qualifies for 
authorship has been omitted from the list, that written authorization has been received 
from all co-authors, that contributors and all funding sources (for authors and 
contributors) have been properly acknowledged and that authors and contributors 
have approved the acknowledgement of their contribution. 
The corresponding author is responsible for ensuring that all authors have seen, 
approved and are fully conversant with the contents of the manuscript. All authors are 
responsible for the accuracy of the manuscript, including all statistical calculations 
and drug doses. 
b) Group authorship 
Results of multicentre studies may be reported under the name of the organizing 
group; however, the group should identify individuals who accept direct responsibility 
for the manuscript. These individuals should meet the criteria for authorship described 
above. If you wish a list of individuals to be credited with authorship, please add an 
asterisk (*) after the name of the group in the byline along with a statement that the 
members of the group are collaborators of the study. The names of group members 




Authors must acknowledge any assistance they received (e.g. provision of writing 
assistance, literature searching, data analysis, administrative support, supply of 
materials). If/how this assistance was funded should be described and included with 
other funding information. Written approval should be obtained from anybody listed 
in acknowledgements, as readers may infer their endorsement of the data and 
conclusions. 
 
4. Submission guidelines 
 
a) Preferred file formats 
Preferred file formats for text and tables are .doc or .rtf. Figures should be .tif or .eps. 
Please note: restricted file extensions are .shs, .zip, .exe, .com, .vbs and .pdf. 
 
b) Title page 
On the title page please state: (1) the title of the article; (2) the name and initials of 
each author; (3) the department(s) and institution(s) to which the work should be 
attributed; (4) the name, postal and e-mail addresses, telephone and facsimile numbers 
of the author responsible for correspondence and to whom requests for reprints should 
be addressed; (5) sources of funding for research and/or publication; (6) the category 
in which the manuscript is being submitted (original article, review, randomized 
clinical trial); and (7) whether the paper is based on a previous communication to a 
society or meeting (with full details). 
 
c) Abstract 
This must contain fewer than 250 words in a structured format. Background: state 
why the study was done, the main aim and the nature of the study (randomized 
clinical trial, retrospective review, experimental study, etc.). Method: describe 
patients, laboratory material and other methods used. Results: state the main findings, 
including important numerical values. Conclusion: state the main conclusions, 
highlighting controversial or unexpected observations. For systematic reviews/meta-
analysis and randomized controlled trials please see guidelines for abstracts as 
reported by PRISMA and CONSORT6,14. 
 
d) Main text 
The main text of the paper should have separate Introduction, Methods, Results and 
Discussion sections (these sections may not be applicable to all article types, e.g. 
Reviews). A short Acknowledgements paragraph may also be included. When 
quoting specific materials, equipment and proprietary drugs, the name and address of 
the manufacturer must be given in parentheses. Generic names should normally be 
used. Any data mentioned in the abstract or discussion must be presented in the 
results section of the main text. 
 
e) Tables and illustrations 
Submit each illustration as a separate file except compound figures e.g. 1a, 1b, 1c, 
etc., which should be supplied as a single file. Please avoid presenting tables in 
landscape format, portrait is preferred. If tables are too large to be displayed in 
portrait format please supply them as supporting information and they will be 
available for download with the published article. Type each table on a separate page 
with a brief title. Supply artwork at the intended size for printing. Line drawings are 
acceptable as clear black on white graphics and must be high quality. Use hatchings, 
not tints. Illustrations should be provided in a ‘true’ figure format (tiff, jpeg, eps, etc.); 
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pdfs, docs, ppts (or any Microsoft Office software format) will not be accepted. All 
illustrations must be supplied at the correct resolution: 
1200 dpi (dots per inch) for black and white line art (simple bar graphs, etc.) 
300 dpi for halftones (black and white photographs) 
600 dpi for combination halftones (photographs that also contain line art such as 
labelling or thin lines) 
Illustrations in colour are encouraged and will be printed at no cost to the author. 
Label each illustration with the figure number and lead author’s name. Indicate the 
top of the illustration and a measure of magnification for photomicrographs. Include 
explanations of symbols and shading within the figure, use arrows to identify 
particular areas of interest. Survival curves must be accompanied by a table giving the 
actual numbers of patients involved and should be truncated when the numbers at risk 
are small; that is, when they are less than one-third of the starting figure. The 
preferred style for health-related quality of life measurements is presentation as radar 
or spider plots, in preference to standard graphs. These plots can be created in excel. 
Include in the legends to illustrations, and the footnotes to tables, brief but 
comprehensive explanations of all the information presented. Look at recent issues of 
the Journal for examples of accepted layout. 
 
f) Videos 
Videos can be submitted with a manuscript online, but it must also be sent under 
separate cover to the Editorial Office with the corresponding manuscript number. If 
an article includes video, the upper right corner of the title page of the manuscript 
must be marked ‘Video is part of article’. 
Formats/File Types: We will accept digital files in MPG4, MP4, MOV, and WMV 
formats. Please upload as a ‘Supplementary File’ on Scholar One. Combined files of a 
manuscript, including video, tables, figures and text must not exceed 100MB. 
Content: Contributors are asked to be succinct, and the Editors reserve the right to 
require shorter video duration. Legends for the video segments should be placed at the 
end of the article. The video should be high quality (both in content and visibility). 
The video should make a specific point; particularly, it should demonstrate the 
features described in the text of the manuscript. In addition, the content of the video 
sequence should directly follow the content of the video legend. The content of the 
video should not display overt product advertising. Educational presentations are 
encouraged. 
Patient Consent: The corresponding author must confirm in the Copyright Transfer 
Agreement (CTA) that he or she has received a signed release form from each patient 
video taped authorizing the offline and/or online distribution of this video material. 
Videos will not be sent out for review until the signed CTA has been received. Ideally 
patients should not be identifiable from the video. 
The Editors reserve the right to request additional video editing by the authors (which 
may delay publication) and to edit video submissions prior to posting and/or 
distribution, including the insertion of a voiceover by the Editor. 
g) Abbreviations 
Avoid using abbreviations. Terms that are mentioned frequently may be abbreviated 
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but only if this does not impair comprehension. Abbreviations must be used 
consistently and must be defined on first use. 
 
h) Numbers and units 
Provide absolute numbers always; percentages may be given in addition but never on 
their own (percentages are not acceptable for sample sizes less than 50). Use the 
decimal point, not a comma; for example 5.7. Use a space and not a comma after 
thousands and multiples thereof; for example 10 000. Use SI units (International 
System of Units) except for the measurement of blood pressure (mmHg). 
 
i) Statistics and design 
Set out clearly the objectives of the study; identify the primary and secondary 
hypotheses, the chosen end-points and justify the sample size with a power 
calculation. 
Clearly describe methods used for analysis; methods not in common usage should be 
referenced. Report results of statistical tests by stating the value of the test statistic, 
the number of degrees of freedom and the P value. Actual P values should always be 
reported to three decimal places, especially when the result is not significant. The 
results of the primary analyses should be reported using confidence intervals instead 
of, or in addition to, P values. For detailed guidance on the handling of statistical 
material consult the article by Murray21. 
 
j) References 
Use double spacing in the Vancouver style. Reference to abstracts and personal 
communications is discouraged. In the text, number references consecutively by 
superscript: e.g. 1 or 1-3. References cited only in tables or figures should be numbered 
in sequence. 
 
5. Copyright and permissions (ownership) 
If your paper is accepted, the author identified as the formal corresponding author for 
the paper will receive an email prompting them to log in to Author Services where, 
via the Wiley Author Licensing Service (WALS), they will be able to complete the 
license agreement on behalf of all authors on the paper. 
 
For authors signing the copyright transfer agreement 
If the OnlineOpen option is not selected the corresponding author will be presented 
with the copyright transfer agreement (CTA) to sign. The terms and conditions of the 
CTA can be previewed in the samples associated with the Copyright FAQs here. 
 
For authors choosing OnlineOpen 
If the OnlineOpen option is selected the corresponding author will have a choice of 
the following Creative Commons License Open Access Agreements (OAA): 
– Creative Commons Attribution Non-Commercial License OAA 
– Creative Commons Attribution Non-Commercial-NoDerivs License OAA 
To preview the terms and conditions of the open access agreements please visit the 
Copyright FAQs hosted on Wiley Author Services here and 
visit http://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright–License.html. 
If you select the OnlineOpen option and your research is funded by the Wellcome 
Trust and members of the Research Councils UK (RCUK) you will be given the 
opportunity to publish your article under a CC-BY license supporting you in 
complying with Wellcome Trust and RCUK requirements. For more information on 
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this policy and the Journal’s compliant self-archiving policy please 
visit http://www.wiley.com/go/funderstatement. 
RCUK and Wellcome Trust authors, please click on the link below to preview the 
terms and conditions of the Creative Commons License. 
To preview the terms and conditions of these open access agreements please visit the 
Copyright FAQs hosted on Wiley Author Services here and 
visit http://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright–License.html. 
It is the authors’ responsibility to obtain written permission to reproduce (in all media, 
including electronic) any material that has appeared previously in another publication. 
Authors should provide copies of permission letters for any material reproduced from 
copyrighted publications. Submitted material will not be returned to the author unless 
specifically requested. 
6. Research ethics 
Human investigation and animal experiments must have local ethics committee 
approval and, if human participants were involved, manuscripts must be accompanied 
by a statement that the experiments were undertaken with the understanding and 
appropriate informed consent of each. Written consent must be obtained from the 
patient (legal guardian or executor, if appropriate) for publication of any detail or 
photograph that might identify an individual. Submit evidence of such consent with 
the manuscript. 
Editors reserve the right to reject papers if there is doubt whether appropriate 
procedures have been followed. 
7. Publication ethics 
 
a) Originality 
On submission of the manuscript the corresponding author must warrant that the 
article is an original work, has not been published before, and is not being considered 
for publication elsewhere in its final form, in either printed or electronic media. 
Publication of abstracts and presentations at scientific meetings will not jeopardize 
full publication. Authors should declare that any republication of the data (e.g. in 
secondary analysis or translation) will not constitute redundant publication, will not 
breach copyright, and will reference the original publication. 
b) Redundant (multiple) publication 
BJS does not consider the following to be prior publication: abstracts and posters at 
conferences, results presented at meetings (for example, to inform investigators or 
participants about findings) and results databases (data without interpretation, 
discussion, context or conclusions in the form of tables and text to describe 
data/information where this is not easily presented in tabular form). Manuscripts that 
have been published previously in another language should state this on the title page 
of the submission. Manuscripts that have been previously published in English that 
are submitted with the aim of serving different audiences are not generally accepted 
by BJS (an exception to this is the publication of substantially shortened Cochrane 
Review articles; see section 2.b). 
Editors may request copies of related publications if they are concerned about overlap 
and possible redundancy. 
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Sub-group analyses, meta-, and secondary analyses should be clearly identified as 
analyses of data that have already been published, and must refer to the primary 
source. 
c) Conflict of interest statements 
All authors must provide details of financial interests (including employment, 
significant share ownership, patent rights, consultancy, research funding, speaker’s 
fees) in a company or institution that might benefit from the publication of the 
submitted article. In addition, authors must provide details of any other potential 
competing interests that readers or editors might consider relevant to their publication 
(for example, political, intellectual, or religious interests). 
 
d) Research and publication misconduct 
BJS adheres to COPE guidelines2 and will pursue cases of suspected research and 
publication misconduct (including falsification, fabrication, plagiarism, inappropriate 
image manipulation, redundant publication and authorship misdemeanours). In such 
cases, BJS will follow the processes set out in the COPE flowcharts22. Authors found 
guilty of misconduct can expect their behaviour to be reported to the head of the 
relevant institution, and details of the case may be highlighted in the pages of the 
journal23. If you have concerns regarding the legitimacy of an article published in 
BJS, please write to the Chief Editor at bjs@wiley.com. 
 
e) Research or publication funding 
Authors must disclose all sources of funding for their research and its publication on 
the title page of the manuscript. Involvement of the funder in study design, data 
collection, data analysis, manuscript preparation and publication decisions should be 
clearly stated, and authors are also asked to confirm that they had complete access to 
the study data that support the publication24. 
 
8. Manuscript submission 
BJS operates an online submission and peer-review system that enables authors to 
submit articles online and track their progress via a web interface. Queries regarding 
Manuscript Central or manuscript submission should be directed to the Editorial 
Office at bjs@wiley.com. 
Manuscripts should be submitted online through ScholarOne Manuscripts 
at http://mc.manuscriptcentral.com/bjs. 
Authors whose first language is not English may wish to consult a specialist English 
language editing/proofing service before submission. Please contact the Editorial 
Office (bjs@wiley.com) if you would like to receive the details of such services. 
 
9. Author resources 
From the Publishers of BJS, Author Resources offers a full menu of customizable 
research capabilities and special features to guide authors through every stage of the 
publication process. Available tools include: Citation Download – download citations 
and abstracts directly into reference management software; Citation Tracking – see 
which other papers have cited the article that you’re currently reading, ToC Alerts – 
sign up to receive tables of content from selected journals; Saved Search Alerts – 
store and re-run detailed search queries, and opt to receive an email each time new 
content matching your defined search is published online. In addition, the ‘Track my 
Articles’ function enables authors to track articles through the BJS publication 
process and opt-in to receive email notification when their article is published online. 
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10. Peer review and editing 
On submission of a manuscript for publication, the submission is checked for 
compliance with these author instructions. If the submission is complete, the Chief 
Editor assesses the manuscript for suitability. A small percentage of manuscripts are 
rejected without peer review at this stage; for example, if the article type is 
inappropriate (e.g., BJS does not publish case reports), if the subject matter is 
unsuitable for the BJS readership (for example, ‘A new method of internal fixation of 
fractures of the fibula’), or if the scientific and/or surgical merit of the paper is flawed 
(for example, if it is not ethical). All other articles are allocated to a specialist Editor, 
who either selects relevant referees for single-blind peer-review (the referees know 
the identity of the authors, but the authors do not know the identity of the referees) or 
consults with at least one other Editor before rejecting the manuscript without peer 
review (for the reasons outlined above). 
This ‘triage’ system of rejecting a small percentage of manuscripts without peer 
review serves two purposes. Firstly, quick decisions on papers unsuitable for BJS 
facilitate submission to another Journal in a timely fashion and, secondly, the 
Journal’s most valuable asset – the referees – are not overloaded with manuscripts 
that will not be accepted for publication. 
Three referees are usually invited to comment on each submission; if the first two 
referee reports are in agreement, a decision is made on the basis of two reports, 
hopefully saving the third referee some valuable time. When the opinions of the 
referees differ significantly, the manuscript is discussed at our monthly Editors’ 
meeting. When a decision has been reached this is communicated to the author. 
Articles not subjected to peer review include solicited Leading Articles (in which case 
the topic and structure of the article is largely designed by the Chief Editor in 
collaboration with the author), Your Views, Book Reviews, and Scientific Surgery, all 
of which are overseen to the highest standards by a dedicated BJS Editor. 
The Editors’ decision is final unless there is a proven to be an error in the process of 
manuscript evaluation or peer review. If you believe that there has been an error of 
process in the handling of your manuscript, please address your concerns to the Chief 
Editor (bjs@wiley.com), quoting the manuscript submission number. 
 
11. Proofing 
On acceptance of a manuscript it is edited by both an Editor and a copy-editor before 
being sent for typesetting. If there are extensive queries at this stage, the authors may 
be asked to provide clarification before the typesetting process. Proofs are sent 
approximately 6–8 weeks after acceptance via e-mail as a link to a PDF file. Acrobat 
Reader will be required in order to read this file – this software can be downloaded 
free of charge25. Further instructions will be sent with the proof. Absent authors 
should arrange for a colleague to access the e-mail to retrieve the proof. 
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